Analysts See $-0.23 EPS for AcelRx Pharmaceuticals, Inc. (ACRX) as of May, 14

April 17, 2018 - By Robert Reynolds

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Corporate Logo
During Q4 2017 the big money sentiment increased to 0.83. That’s change of 0.13, from 2017Q3’s 0.7. 8 investors sold all, 15 reduced holdings as AcelRx Pharmaceuticals, Inc. ratio is positive. 12 increased holdings while 7 funds bought holdings. Funds hold 4.57 million shares thus 31.27% less from 2017Q3’s 6.65 million shares.
Quantitative Investment Mgmt Lc reported 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Guggenheim Limited Liability Corp reported 0% stake. The New York-based Bancorporation Of Mellon has invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Virtu Financial Limited Liability Company has 0.01% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). 17,537 were reported by Morgan Stanley. Geode Cap Ltd Limited Liability Company has 215,834 shs for 0% of their capital. Two Sigma Secs Limited Company invested in 35,676 shs or 0% of the stock. Citadel Advsr Limited Company stated it has 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Creative Planning has 13,700 shs for 0% of their capital. Geller Family Office Ltd Llc reported 275,000 shs stake. Bnp Paribas Arbitrage Sa owns 8 shs for 0% of their capital. State Street holds 39,856 shs. Blackrock reported 647,467 shs. Barclays Pcl invested in 904 shs. The New York-based Art Advsrs Limited Liability has invested 0.01% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX).

Earnings report for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is anticipated On May, 14., according to Zacks. The EPS diference is $0.11 or 32.35 % up from last years number. Previous year: $-0.34; Analysts forcast: $-0.23. 15.00 % negative EPS growth is what Wall Street’s predicts after $-0.20 reported EPS last quarter. Its shares touched $2.4 on during the last trading session after 6.67% change.AcelRx Pharmaceuticals, Inc. is downtrending after having declined 27.87% since April 17, 2017. ACRX has 1.00M volume or 110.42% up from normal. The stock underperformed the S&P 500 by 39.42%.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.The firm is valued at $122.16 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain.Currently it has negative earnings. The company's late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: